ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.068,21
0,26%
S&P 500
5.473,23
0,77%
Dow Jones
38.778,10
0,49%
Euro vs US Dollar
1,07398
-0,01%
Bitcoin
66.292,27
-0,29%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Chemgenex Pharmaceuticals Ltd (MM) (CXSP)

  7. Chemgenex Pharmaceuticals Ltd (MM) (CXSP) News

CXSP

Chemgenex (CXSP)

Chemgenex Pharmaceuticals Ltd (MM)
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:CXSP
DatumZeitQuelleÜberschriftSymbolFirma
29/06/200915h19Edgar (US Regulatory)Report of Foreign Issuer (6-K)NASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
01/06/200918h00Business WirePivotal Study Results: ChemGenex’s Omacetaxine May Provide the First Viable Drug Treatment Option for Patients With a Highl...NASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
22/05/200912h17Edgar (US Regulatory)Report of Foreign Issuer (6-K)NASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
21/05/200913h00Business WireChemGenex’s Omacetaxine to be Showcased in Three Oral Presentations at EHANASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
18/05/200921h07Edgar (US Regulatory)Report of Foreign Issuer (6-K)NASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
15/05/200901h30Business WireChemGenex to Present Pivotal Data in T315I Positive CML Patients as Oral Presentation at ASCONASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
04/05/200916h54Edgar (US Regulatory)Report of Foreign Issuer (6-K)NASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
09/04/200912h00Business WireChemGenex Completes Capital Raising, Announces Rights IssueNASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
31/03/200913h09Edgar (US Regulatory)Report of Foreign Issuer (6-K)NASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
26/03/200911h40Business WireNew Data Suggesting that ChemGenex’s Omacetaxine Can Eradicate Leukemic Stem Cells May Offer a Breakthrough in Treating CMLNASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
20/01/200918h10Edgar (US Regulatory)Report of Foreign Issuer (6-K)NASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
15/01/200916h45Edgar (US Regulatory)Report of Foreign Issuer (6-K)NASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
30/12/200820h00Edgar (US Regulatory)Annual and Transition Report (foreign private issuer) (20-F)NASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
09/12/200817h28Edgar (US Regulatory)Report of Foreign Issuer (6-K)NASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
16/06/200821h04Edgar (US Regulatory)Chemgenex Pharmaceuticals Ltd - Report of Foreign Issuer (6-K)NASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
01/04/200816h59Edgar (US Regulatory)Chemgenex Pharmaceuticals Ltd - Report of Foreign Issuer (6-K)NASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
01/04/200814h00Business WireChemGenex Investigators Present Data on Clinical Activity of Omacetaxine in Imatinib-Resistant Chronic Myeloid Leukemia PatientsNASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
29/02/200818h41Edgar (US Regulatory)Chemgenex Pharmaceuticals Ltd - Report of Foreign Issuer (6-K)NASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
07/01/200813h41Edgar (US Regulatory)Chemgenex Pharmaceuticals Ltd - Report of Foreign Issuer (6-K)NASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
03/01/200816h55Edgar (US Regulatory)Chemgenex Pharmaceuticals Ltd - Report of Foreign Issuer (6-K)NASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
27/11/200723h25Edgar (US Regulatory)Chemgenex Pharmaceuticals Ltd - Annual and Transition Report (foreign private issuer) (20-F)NASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
30/10/200717h02Edgar (US Regulatory)Chemgenex Pharmaceuticals Ltd - Report of Foreign Issuer (6-K)NASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
30/10/200717h02Edgar (US Regulatory)Chemgenex Pharmaceuticals Ltd - Report of Foreign Issuer (6-K)NASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
01/10/200716h41Edgar (US Regulatory)Chemgenex Pharmaceuticals Ltd (Other) (6-K)NASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
11/06/200722h30Business WireChemGenex Announces Publication Confirming Activity of Ceflatonin(R) in T315I-Positive CMLNASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
03/04/200704h27Business WireChemGenex Announces the Completion of A$21 Million FinancingNASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
05/01/200718h08Business WireChemGenex Pharmaceuticals: Announcement Pursuant To Nasdaq Marketplace Rule 4350(b)NASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
04/04/200614h00PR Newswire (US)Preclinical Progress Reported at American Association of Cancer Research ConferenceNASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
23/03/200600h26PR Newswire (US)New Preclinical Research Supports Ceflatonin(R) in Treatment of Acute Myeloid Leukemia (AML)NASDAQ:CXSP
20/03/200605h40PR Newswire (US)Orphan Drug Designation Granted by the U.S. FDA for Ceflatonin(R)NASDAQ:CXSPChemgenex Pharmaceuticals Ltd (MM)
 Showing the most relevant articles for your search:NASDAQ:CXSP

Kürzlich von Ihnen besucht

NYSE
MCD
McDonalds
CCOM
US30
US 30
COIN
ETHUSD
Ethereum
PM
XAUUSD
Gold vs US Dollar
TG
MBG
MercedesBenz
AMEX
XLF
Financial Select Sector
USOTC
RHHBY
Roche (QX)
USOTC
ADDYY
Adidas (QX)
NASDAQ
GOOGL
Alphabet
DBI
SDXP
SDAX
NASDAQ
AMZN
Amazon.com
USOTC
DTEGY
Deutsche Telekom (QX)
NASDAQ
AAPL
Apple
USOTC
BNPQY
BNP Paribas (QX)
TG
BAS
BASF
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten